Accentia increases pain management options

Through its manufacturing subsidiary, Teamm Pharmaceuticals, Accentia will now be able to produce a new dosage of Xodol (hydrocodone bitartrate and acetaminophen tablets, USP), giving physicians additional choices and treatment options for pain patients.

Xodol combines hydrocodone, a narcotic widely used for pain, and the lowest effective dose of acetaminophen, the most commonly used analgesic. This formula provides physicians with effective pain-management combinations, reducing the possibility that the patient will exceed the recommended daily allowance of acetaminophen.

The recommended daily dose of acetaminophen is up to 4,000 mg per day for less than 10 days, and no more than 2,600 mg per day for longer-term use. Higher cumulative doses of acetaminophen have been shown to predispose patients to serious adverse effects including liver damage.

“Xodol is a unique dosage product in that it combines an effective narcotic, hydrocodone, with a very commonly used analgesic, acetaminophen, in a lower dose of acetaminophen than is available in other combination pain medications. This addition to our pain franchise allows the physician to prescribe Xodol and tailor the dosing to effectively manage the individual patient’s pain threshold,” said Gary Cantrell, Teamm Pharmaceuticals executive vice president of sales and marketing.